首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1724758

蛋白質藥物：全球市場與製造技術

Global Markets and Manufacturing Technologies for Protein Drugs

出版日期: 2025年04月30日 | 出版商:

BCC Research | 英文 162 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球蛋白質藥物市場規模預計將從 2024 年的 4,417 億美元成長到 2029 年底的 6,557 億美元，2024 年至 2029 年的複合年成長率為 8.2%。

預計北美市場將從 2024 年的 2,359 億美元擴大到 2029 年底的 3,469 億美元，同期的複合年成長率為 8.0%。預計歐洲市場將從 2024 年的 1,152 億美元成長到 2029 年底的 1,661 億美元，預測期內的複合年成長率為 7.6%。

本報告調查了全球蛋白質藥物市場，並總結了市場概況、市場影響因素和市場機會分析、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

全球市場動態
市場促進因素
製造技術的進步
持續推出新產品
癌症發生率增加
市場限制
蛋白質藥物高成本
複雜的監理程序
市場挑戰
專利到期和獨佔權喪失
蛋白質藥物的穩定性與遞送
市場機會
越來越多的單株抗體核准
授權和合作協議

第4章監管情況

監管情景
價格監管

第5章新興技術

概述
蛋白質藥物市場的新興技術
雙特異性和多特異性抗體
抗體藥物複合體
抗體融合蛋白
蛋白質藥物市場中的人工智慧

第6章市場區隔分析

概述
細分市場
全球蛋白質藥物市場（按類型）
單株抗體
肽激素
疫苗
血液因素
細胞激素
治療性酵素
胜肽類抗生素
融合蛋白
全球蛋白質治療市場（按製造技術）
細胞培養
微生物發酵
天然來源
受精卵
化學合成
基因改造
按地區分類的市場
全球蛋白質藥物市場（按地區）
北美洲
歐洲
亞太地區
其他地區

第7章競爭訊息

產業結構
2023年領先的蛋白質藥物
市場佔有率分析
單株抗體
肽激素
戰略分析
獲得
產品核可
協議和夥伴關係
其他策略

第8章蛋白質藥物市場的永續性：ESG 視角

蛋白質製藥業的永續性
ESG風險評估：理解數據
ESG績效分析
環境績效
社會績效
管治績效
結論

第9章附錄

調查方法
簡稱
參考
公司簡介
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.

簡介目錄圖表

Product Code: BIO021G

The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

The North American protein drugs market is expected to grow from $235.9 billion in 2024 and is projected to reach $346.9 billion by the end of 2029, at a CAGR of 8.0% during the forecast period of 2024 to 2029.

The European protein drugs market is expected to grow from $115.2 billion in 2024 and is projected to reach $166.1 billion by the end of 2029, at a CAGR of 7.6% during the forecast period of 2024 to 2029.

Report Scope

The report analyzes trends in the global market for protein drugs and manufacturing technologies. The report includes global revenue ($ millions) for the base year of 2023 and estimated data for the forecast period of 2024 through 2029. The market is segmented by product type/subtype, manufacturing technology and region. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.

The report focuses on the trends and challenges that affect the market and the vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the rankings and market shares of leading companies in the protein drug market. It also has a section of company profiles that shows financials, product portfolios and recent developments.

Report Includes

79 data tables and 57 additional tables
An analysis of the global markets for protein drugs and their manufacturing technologies
Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the size of and revenue prospects for the global market, along with a market share analysis by type of protein drug, manufacturing technology, and region
Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Analysis of the advances in manufacturing technologies, disease prevalence trends, new products , and the impact of biosimilars entering the market for protein drugs
An analysis of patents and significant patent grants
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including AbbVie Inc., Bristol Myer Squibb, Merck & Co., Novo Nordisk S/A, Sanofi, and Roche

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Current and Future Market Overview
Technology Background
Pharmacological Classification of Therapeutic Proteins
Protein Therapeutics with Enzymatic or Regulatory Activity
Protein Therapeutics with Special Targeting Activity
Protein Vaccines
Characteristics of Therapeutic Proteins
Macroeconomic Factors
Porter's Five Forces Analysis
Potential for New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Competition in the Industry
Supply Chain Analysis
R&D
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies/Hospitals
Dispensed to Consumers

Chapter 3 Market Dynamics

Global Market Dynamics
Market Drivers
Advances in Manufacturing Technologies
Continuous Product Launches
Increasing Incidence of Cancer
Market Restraints
High Costs of Protein Drugs
Complex Regulatory Procedures
Market Challenges
Patent Expiration and Loss of Exclusivity
Protein Drugs Stability and Delivery
Market Opportunities
Increasing Number of Approvals for MAbs
Licensing and Collaboration Agreements

Chapter 4 Regulatory Landscape

Regulatory Scenario
Price Regulations

Chapter 5 Emerging Technologies

Overview
Emerging Technologies in Protein Drugs Market
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI in the Protein Drug Market

Chapter 6 Market Segment Analysis

Overview
Segmentation Breakdown
Global Market for Protein Drugs, by Type
MAbs
Peptide Hormones
Vaccines
Blood Factors
Cytokines
Therapeutic Enzymes
Peptide Antibiotics
Fusion Proteins
Global Market for Protein Drugs, by Manufacturing Technology
Cell Culture
Microbial Fermentation
Natural Source
Embryonated Egg
Chemical Synthesis
Transgenics
Market Breakdown by Region
Global Market for Protein Drugs, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Industry Structure
Leading Protein Drugs, 2023
Market Share Analysis
MAbs
Peptide Hormones
Strategic Analysis
Acquisitions
Product Approvals
Agreements and Partnerships
Other Strategies

Chapter 8 Sustainability in the Protein Drug Market: ESG Perspective

Sustainability in the Protein Drug Industry
ESG Risk Ratings: Understanding the Data
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks

Chapter 9 Appendix

Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.

簡介目錄圖表

List of Tables

Summary Table : Global Market for Protein Drugs, by Region, Through 2029
Table 1 : Evolution of Therapeutic Proteins, 1950s to Present
Table 2 : Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
Table 3 : Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 4 : Global Market for Protein Drugs, by Type, Through 2029
Table 5 : Global Market for MAbs, by Type, Through 2029
Table 6 : Global Market for MAbs, by Region, Through 2029
Table 7 : Global Market for Human MAbs, by Region, Through 2029
Table 8 : Global Market for Humanized MAbs, by Region, Through 2029
Table 9 : Global Market for Chimeric MAbs, by Region, Through 2029
Table 10 : Global Market for Murine MAbs, by Region, Through 2029
Table 11 : Global Market for Peptide Hormones, by Type, Through 2029
Table 12 : Global Market for Peptide Hormones, by Region, Through 2029
Table 13 : Global Market for Insulin, by Region, Through 2029Global Market for Insulin, by Region, Through 2029
Table 14 : Global Market for EPO, by Region, Through 2029
Table 15 : Global Market for Growth Hormones, by Region, Through 2029
Table 16 : Global Market for Other Peptide Hormones, by Region, Through 2029
Table 17 : Global Market for Protein Vaccines, by Type, Through 2029
Table 18 : Global Market for Protein Vaccines, by Region, Through 2029
Table 19 : Global Market for Bacterial Vaccines, by Region, Through 2029
Table 20 : Global Market for Viral Vaccines, by Region, Through 2029
Table 21 : Global Market for Other Protein Vaccines, by Region, Through 2029
Table 22 : Global Market for Blood Factors, by Type, Through 2029
Table 23 : Global Market for Blood Factors, by Region, Through 2029
Table 24 : Global Market for Coagulation Factors, by Region, Through 2029
Table 25 : Global Market for Immunoglobulins, by Region, Through 2029
Table 26 : Global Market for Other Blood Factors, by Region, Through 2029
Table 27 : Global Market for Cytokines, by Type, Through 2029
Table 28 : Global Market for Cytokines, by Region, Through 2029
Table 29 : Global Market for Interleukins, by Region, Through 2029
Table 30 : Global Market for Interferons, by Region, Through 2029
Table 31 : Global Market for G-CSF, by Region, Through 2029
Table 32 : Global Market for Therapeutic Enzymes, by Type, Through 2029
Table 33 : Global Market for Therapeutic Enzymes, by Region, Through 2029
Table 34 : Global Market for Lysosomal Enzymes, by Region, Through 2029
Table 35 : Global Market for Thrombolytic Enzymes, by Region, Through 2029
Table 36 : Global Market for Pancreatic Enzymes, by Region, Through 2029
Table 37 : Global Market for Peptide Antibiotics, by Type, Through 2029
Table 38 : Global Market for Peptide Antibiotics, by Region, Through 2029
Table 39 : Global Market for Cyclosporine, by Region, Through 2029
Table 40 : Global Market for Vancomycin, by Region, Through 2029
Table 41 : Global Market for Other Peptide Antibiotics, by Region, Through 2029
Table 42 : Global Market for Fusion Proteins, by Region, Through 2029
Table 43 : Global Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 44 : Global Market for Cell Culture, by Region, Through 2029
Table 45 : Global Market for Microbial Fermentation, by Region, Through 2029
Table 46 : Global Market for Natural Source Protein Manufacturing Technology, by Region, Through 2029
Table 47 : Global Market for Embryonated Egg Protein Manufacturing Technology, by Region, Through 2029
Table 48 : Global Market for Chemical Synthesis Protein Manufacturing Technology, by Region, Through 2029
Table 49 : Global Market for Transgenics Protein Manufacturing Technology, by Region, Through 2029
Table 50 : Global Market for Protein Drugs, by Region, Through 2029
Table 51 : North American Market for Protein Drugs, by Type, Through 2029
Table 52 : North American Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 53 : North American Market for Protein Drugs, by Country, Through 2029
Table 54 : Estimated Incidence of Cancer Cases in the EU, by Country, 2022
Table 55 : Therapeutic MAbs Approved or Under Review in the EU, 2023 and 2024
Table 56 : European Market for Protein Drugs, by Type, Through 2029
Table 57 : European Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 58 : European Market for Protein Drugs, by Country, Through 2029
Table 59 : Asia-Pacific Market for Protein Drugs, by Type, Through 2029
Table 60 : Asia-Pacific Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 61 : Asia-Pacific Market for Protein Drugs, by Country, Through 2029
Table 62 : RoW Market for Protein Drugs, by Type, Through 2029
Table 63 : RoW Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 64 : RoW Market for Protein Drugs, by Sub-Region, Through 2029
Table 65 : Leading Protein Drugs, 2023
Table 66 : Acquisitions in the Protein Drug Market, 2022-2024
Table 67 : Product Approvals in the Protein Drug Market, 2022-2024
Table 68 : Agreements and Partnerships in the Protein Drug Market, 2022-2025
Table 69 : Other Strategies in the Protein Drug Market, 2022-2024
Table 70 : Focus Areas in ESG Metrics
Table 71 : ESG Rankings for Major Protein Drug Companies, 2024*
Table 72 : ESG: Environmental Overview
Table 73 : ESG: Social Factors Overview
Table 74 : ESG: Governance Overview
Table 75 : Abbreviations Used in this Report
Table 76 : AbbVie Inc.: Company Snapshot
Table 77 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 78 : AbbVie Inc.: Product Portfolio
Table 79 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 80 : Amgen Inc.: Company Snapshot
Table 81 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 82 : Amgen Inc.: Product Portfolio
Table 83 : Amgen Inc.: News/Key Developments, 2022-2024
Table 84 : AstraZeneca: Company Snapshot
Table 85 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 86 : AstraZeneca: Product Portfolio
Table 87 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 88 : Bayer AG: Company Snapshot
Table 89 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 90 : Bayer AG: Product Portfolio
Table 91 : Bayer AG: News/Recent Developments, 2024
Table 92 : Bristol-Myers Squibb Co.: Company Snapshot
Table 93 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 94 : Bristol-Myers Squibb Co.: Product Portfolio
Table 95 : Bristol-Myers Squibb Co.: News/Key Developments, 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 97 : F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 98 : F. Hoffman-La Roche Ltd.: Product Portfolio
Table 99 : F. Hoffman-La Roche Ltd.: News/Key Developments, 2023 and 2024
Table 100 : Johnson & Johnson Services Inc.: Company Snapshot
Table 101 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 102 : Johnson & Johnson Services Inc.: Product Portfolio
Table 103 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 104 : Lilly: Company Snapshot
Table 105 : Lilly: Financial Performance, FY 2022 and 2023
Table 106 : Lilly: Product Portfolio
Table 107 : Lilly: News/Key Developments, 2023 and 2024
Table 108 : Merck & Co. Inc.: Company Snapshot
Table 109 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 110 : Merck & Co. Inc.: Product Portfolio
Table 111 : Merck & Co. Inc.: News/Key Developments, 2022-2024
Table 112 : Novartis AG: Company Snapshot
Table 113 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 114 : Novartis AG: Product Portfolio
Table 115 : Novartis AG: News/Key Developments, 2022-2024
Table 116 : Novo Nordisk A/S: Company Snapshot
Table 117 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 118 : Novo Nordisk A/S: Product Portfolio
Table 119 : Novo Nordisk A/S: News/Key Developments, 2023-2025
Table 120 : Pfizer Inc.: Company Snapshot
Table 121 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 122 : Pfizer Inc.: Product Portfolio
Table 123 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 124 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 125 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 126 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 127 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022 and 2023
Table 128 : Sanofi: Company Snapshot
Table 129 : Sanofi: Financial Performance, FY 2022 and 2023
Table 130 : Sanofi: Product Portfolio
Table 131 : Sanofi: News/Key Developments, 2022-2024
Table 132 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 133 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 134 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 135 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2022-2024

List of Figures

Summary Figure : Global Market Shares of Protein Drugs, by Region, 2023
Figure 1 : Desirable Characteristics of Therapeutic Proteins
Figure 2 : Porter's Five Forces Analysis: Protein Drug Market
Figure 3 : Supply Chain of Protein Drugs
Figure 4 : Market Dynamics Snapshot
Figure 5 : Emerging Technologies in the Protein Drugs Market
Figure 6 : Global Market Shares of Protein Drugs, by Type, 2023
Figure 7 : Global Market Shares of MAbs, by Type, 2023
Figure 8 : Global Market Shares of Peptide Hormones, by Type, 2023
Figure 9 : Global Market Shares of Protein Vaccines, by Type, 2023
Figure 10 : Global Market Shares of Blood Factors, by Type, 2023
Figure 11 : Global Market Shares of Cytokines, by Type, 2023
Figure 12 : Global Market Shares of Therapeutic Enzymes, by Type, 2023
Figure 13 : Global Market Shares of Peptide Antibiotics, by Type, 2023
Figure 14 : Global Market Shares of Protein Drugs, by Manufacturing Technology, 2023
Figure 15 : Global Market Shares of Protein Drugs, by Region, 2023
Figure 16 : North American Market Shares of Protein Drugs, by Country, 2023
Figure 17 : U.S. Elderly Population (65 and Older), 2010-2050
Figure 18 : European Market Shares of Protein Drugs, by Country, 2023
Figure 19 : Asia-Pacific Market Shares of Protein Drugs, by Country, 2023
Figure 20 : RoW Market Shares of Protein Drugs, by Sub-Region, 2023
Figure 21 : Global Market Shares of MAbs, by Company, 2023
Figure 22 : Global Market Shares of Peptide Hormones, by Company, 2023
Figure 23 : Business Benefits of a Strong ESG Proposition
Figure 24 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 25 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 26 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 27 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 28 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 29 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 30 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 31 : Bayer AG: Revenue Shares, by Region/Country, FY 2023
Figure 32 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 33 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 34 : F. Hoffman-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 35 : F. Hoffman-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 36 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 37 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 38 : Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 39 : Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 40 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 43 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 44 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
Figure 45 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
Figure 46 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 47 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 48 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 49 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 51 : Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 52 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 53 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Region, FY 2023